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Abstract 
This study was carried out to assess accuracy of Omnican® insulin pen needles (29G and 30G) by 
measuring the weight of insulin delivered in each of 10 depressions of the plunger comparing these 
using other pen-injectors (Humapen® and Novopen®) for each gauge. We found that the needle-to 
needle variation was not statistically significant when the needles were used to dispense insulin using 
either of the insulin pens (Humapen® and Novopen®). HumaPen® insulin pen was found to deliver the 
insulin closer to set target volume using either gauge (29G and 30G) of the Omnican® needles in some 
of the insulin ranges used in this study. 
Introduction 
In diabetic patients requiring insulin for control, it is important to ensure that the dosage 
prescribed is the dose delivered to the patient. Variation in dose delivery may lead to poor 
control (either hyperglycemia or hypoglycemia) of diabetes. One reason for the variation is due 
to the inaccurate measurements in dispensing due to poor delivery devices. 
Many adults who are diabetic may require insulin daily injections. Insulin injection can 
be a problem be it in the adolescents or children. There are reports that question the accuracy of 
patients and health professionals in preparing the split-mix of insulin therapy1. This problem 
has become more acute in the U.K., where the more dilute U40/ml and U80/ml insulin were 
withdrawn and have been replaced with the U100/ml insulin2. Although this simplified 
treatment and reduced the potential for dosage errors, it meant that insulin had to be dispensed 
in extremely small volumes. Consequently, the use of conventional syringes to administer 
insulin becomes less possible as the syringes have an unacceptable large error3. 
In the U.K., a variety of pen-injector devises such as NovoPen®4,5  and HumaPen®6 were 
used to ensure that small doses are administered more accurately. In addition, these pens 
minimised potential dosage errors. Patients who have used some of the pen-injectors have 
expressed satisfaction in using this device to administer their daily insulin injections. The 
patients felt more at ease using the pen-injectors to administer insulin and it also gave them 
flexibility of lifestyle. 
There are several studies7, 8 that recommend the use of multiple daily injections with 
insulin pens in children and adolescents with diabetes. 
In this study we assessed the repeatability and reproducibility of two gauges of 
Omnican® pen needles using two well-established insulin pens, HumaPen®6 and NovoPen®5. 
Materials and methods 
 
Insulin pens NovoPen® and Eli Lily’s HumaPen® were used for testing in the study. Both 
pens and the corresponding insulin cartridges were obtained from the respective suppliers. 
Omnican® needles Omnican® needles gauge 29 and 30 were tested in the study. The needles 
were provided by B. Braun Medical Supplies (M) Sdn. Bhd. 
Volunteers Random selection of thirty volunteers of which fifteen were females, aged 40 
years and above. Just prior to the study, all the volunteers were taught on how to use the 
NovoPen® and HumaPen® insulin pen. 
Experimental design 
Two gauges (29G and 30G) of the Omnican® pen needle and two insulin pens (HumaPen® 
and NovoPen®) were tested. For each needle gauge the volunteers were asked to dispense 1-
10 depressions per needle gauge of the plunger and this was compared with similar 
measurements using other pen-injectors for each gauge. For both needle gauges and insulin 
pens, four insulin volumes were tested i.e. 60 units (one depressions per needle per pen), 20 
units (five depressions per needle per pen) and 15 units (ten depressions per needle per pen). 
The volunteers dispensed the relevant amount of insulin into pre-weighed tubes. Three trials 
were done for all the tested ranges, pens and also needles. The tubes were weighed 
immediately and the amount of insulin dispensed calculated. 
Statistical analysis Gauge Repeatability and Reproducibility (GRR) with Nested Design 
method9 model was chosen. The data obtained from the study were analysed using the 
Analysis of Variance (ANOVA) method. 
 
Results 
The summary of results is shown in Table-1. The tolerance applied is based on target value ± 
5%. The results show that there is no significant needle-to-needle variations when the both 
types of needles (29G and 30G) are used to dispense insulin with both the insulin pens tested 
(Humapen® and Novopen®). 
Table 1 
Gauge Tolerance % Needle-To-Needle Variation 
p-value 
(needle variation)* 
HP60 (0.6 ± 0.03) g 11.68% 0.408 
NP60 (0.6 ± 0.03) g 0.00% 0.794 
HP20 (1.0 ±0.05) g 28.47% 0.710 
NP20 (1.0 ± 0.05) g 0.00% 0.584 
HP15 (1.50 ± 0.075) g 23.53% 0.204 
NP15 (1.50 ± 0.075) g 0.00% 0.997 
(Note: * As p>0.05, the contribution of needle-to-needle variation is not significant with reference to the 
indicated tolerance. Variations due to user and insulin pens are not included.) 
 
 Table 1: Summary of results. 
Two Omnican® pen needle gauges (29G and 30G) and two insulin pens, HumaPen® (HP) and 
NovoPen® (NP) were tested. The volunteers were asked to dispense 1-10 depressions of the 
insulin pen and this was compared with similar measurements using other pen-injector for 
each gauge. The insulin volumes tested were 60 units, 20 units and 15 units. The data 
obtained was analysed using the ANOVA and GRR statistical method. The tolerance applied 
is based on (target value ± 5%). 
 
(Note: Numbers after HP and NP refer to the volume of insulin dispensed, e.g. HP60 = 60 units of 
insulin using the HumaPen®; NP15 = 15 units of insulin using the NovoPen®) 
 
Table 2 
HumaPen® NovoPen® 
(29G) 
 
(29G) Method 
Target value 
(insulin units) Average S.D. Average S.D. 
ANOVA 
60 0.60 0.594 0.011 0.598 0.011 0.199 
20 1.00 0.994 0.010 0.989 0.015 0.124 
15 1.50 1.495 0.022 1.464 0.030 0.000*  
HumaPen® NovoPen® 
(30G) 
 
(30G) Method 
Target value 
(insulin units) 
Average S.D. Average S.D. 
ANOVA 
60 0.60 0.596 0.008 0.594 0.009 0.474 
20 1.00 0.999 0.013 0.989 0.012 0.003* 
15 1.50 1.489 0.019 1.464 0.025 0.000* 
(Note: * Statistically significant as p< 0.05) 
 
Table 2: The above results are obtained via one-factor ANOVA. The factor being studied is 
the insulin pens i.e. HumaPen® (HP) and NovoPen® (NP) pens. 
 
The ability of the HumaPen® to deliver insulin nearer to the set target set value was shown to 
be statistically significant (see Table-2) when the pen was used to deliver 15 units of insulin 
using the both the Omnican® needles. With the 29G needle, the HumaPen® was also able to 
deliver closer to set target value when it was used to dispense 20 units of insulin (see Table-
2) 
Discussion 
 
The GRR with Nested Design was chosen and ANOVA method was used to analyse the data 
for two reasons. The first being that the needles used in this trial are ‘nested’ to the users. This 
is different from the conventional GRR study where the gauges are shared among the users. 
This study simulates the actual situation when the pens are to be used by diabetic patients 
where sharing of needles does not usually take place. The second reason for choosing this 
approach was that the GRR (ANOVA) method provides variance components for ‘needle to 
needle’ variation in addition to the repeatability and reproducibility variations. Based on the p-
value obtained from ANOVA results at significance level of 0.05, the needle-to-needle 
variation is not significant when the needles (30G & 29G) are used for dispensing volumes of 
insulin i.e. 60, 20 and 15 units using either of the insulin pens tested (see Table-1). Variations 
due to users and insulin pens were not included in the scope of this study. Nevertheless, the user 
variations in using the gauges (pen and needles) may be improved when they get familiar with 
the gauges. The ability of the HumaPen® to deliver nearer to set target value was also shown to 
be statistically significant with some of the insulin volume tested (see Table-2). 
Based on the results from this study, we would recommend that it is compatible for all volume 
of insulin up to 15 units dispensed using both the gauges of the Omnican pen needles with 
NovoPen® and HumaPen®. With the results of the data in mind, we could extrapolate that we 
can use both gauges of the Omnican® pen needles for dispensing lower volume of insulin. We 
will be conducting further testing for ranges between 15 and 5 units of insulin and also to 
study the impact of insulin pen and user variation in using the Omnican® needles. In 
conclusion, we observed consistency in the dispensing of insulin using the both gauges (30G 
and 29G) Omnican® needles using the NovoPen® while we found that the HumaPen® was able 
to deliver insulin nearer to the set target values (see Table-2). 
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